edoxaban tosylate (BioDeep_00000701990)
代谢物信息卡片
edoxaban tosylate
化学式: C31H38ClN7O7S2 (719.1962548000001)
中文名称: 伊多塞班对甲苯磺酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
InChI: /m0./s1
描述信息
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:85975
- KEGGdrug: D11568
- PubChem: 44610678
- ChEMBL: CHEMBL2105682
- CAS: 480449-71-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y H Lip. Clinical Outcomes in Elderly Atrial Fibrillation Patients at Increased Bleeding Risk Treated with Very-Low-Dose versus Regular-Dose Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.
European heart journal. Cardiovascular pharmacotherapy.
2023 Aug; ?(?):. doi:
10.1093/ehjcvp/pvad058. [PMID: 37580139] - Giuseppe Derosa, Manfredi Rizzo, Natale Daniele Brunetti, Riccardo Raddino, Mara Gavazzoni, Gianfranco Pasini, Giovanni Gaudio, Antonio Maggi, Angela D'Angelo, Luisa De Gennaro, Pamela Maffioli. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).
Journal of diabetes and its complications.
2023 08; 37(8):108512. doi:
10.1016/j.jdiacomp.2023.108512. [PMID: 37390799] - Ophelia Yin, Tarundeep Kakkar, Anil Duggal, Masakatsu Kotsuma, Minggao Shi, Hans Lanz, Michael A Grosso. Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.
Clinical pharmacology in drug development.
2022 05; 11(5):666-674. doi:
10.1002/cpdd.1050. [PMID: 34877813] - Md Abdur Rashid, Saiqa Muneer, Yahya Alhamhoom, Nazrul Islam. Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban.
Biomolecules.
2022 04; 12(4):. doi:
10.3390/biom12040590. [PMID: 35454179] - Lixin Fang, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Hiroshi Kawanishi, Tomonobu Takikawa, Yuta Ozaki, Kunihiko Takahara, Minako Tatsumi, Mikito Takefuji, Toyoaki Murohara, Noriyuki Ouchi. Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.
Physiological reports.
2022 03; 10(5):e15218. doi:
10.14814/phy2.15218. [PMID: 35262272] - Tetsuro Yoshida, Akihiro Nakamura, Junichi Funada, Mari Amino, Wataru Shimizu, Masayuki Fukuzawa, Saori Watanabe, Takuya Hayashi, Takeshi Yamashita, Ken Okumura, Masaharu Akao. Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.
Circulation.
2022 03; 145(9):718-720. doi:
10.1161/circulationaha.121.057190. [PMID: 35226559] - Tetsuji Shinohara, Naohiko Takahashi, Yasushi Mukai, Tetsuya Kimura, Keita Yamaguchi, Atsushi Takita, Hideki Origasa, Ken Okumura. Catheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use - A Subanalysis of KYU-RABLE.
Circulation journal : official journal of the Japanese Circulation Society.
2022 01; 86(2):280-286. doi:
10.1253/circj.cj-21-0247. [PMID: 34275977] - L Puccetti, V Sammartano, P Calzoni, F Bacchiarri, A Santoni, D Fineschi, M Bocchia. Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
European review for medical and pharmacological sciences.
2022 01; 26(1):54-58. doi:
10.26355/eurrev_202201_27747. [PMID: 35049019] - Francisco J Guerrero-Márquez, Ignacio Sainz-Hidalgo, Pablo Cristobo Sainz, Inmaculada Sigler Vilches, Alberto Avilés Toscano, Basilio Soto-Espinosa de Los Monteros. [Effectiveness of the EQ-5D and CRES-4 questionnaire for assessing the impact on the quality of life of patients and the level of satisfaction after exchanging dicumarinics for edoxabán: Real-life experience based on a multicentre study].
Medicina clinica.
2021 12; 157(11):530-534. doi:
10.1016/j.medcli.2020.07.032. [PMID: 33059936] - Andrea Rubboli, Claudio Fresco, Maurizio Paciaroni, Bianca Rocca, Domenico Pecora, Iolanda Enea, Claudio Cuccia, Giuseppe Patti. How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Journal of cardiovascular medicine (Hagerstown, Md.).
2021 Dec; 22(11):924-928. doi:
10.2459/jcm.0000000000001204. [PMID: 33927142] - Md Abdur Rashid, Saiqa Muneer, Jayanti Mendhi, Mohammad Zaidur Rahman Sabuj, Yahya Alhamhoom, Yin Xiao, Tony Wang, Emad L Izake, Nazrul Islam. Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
International journal of pharmaceutics.
2021 Oct; 608(?):121122. doi:
10.1016/j.ijpharm.2021.121122. [PMID: 34560207] - Katharina Thuile, Katia Giacomuzzi, Erika Jani, Peter Marschang, Thomas Mueller. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Scandinavian journal of clinical and laboratory investigation.
2021 Oct; 81(6):461-468. doi:
10.1080/00365513.2021.1946844. [PMID: 34278897] - Valerio Langella, Roberta Bottino, Antonio Asti, Giulio Maresca, Gisella Di Palma, Domenico Pomponi, Claudia Sassone, Egidio Imbalzano, Vincenzo Russo. Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Expert review of clinical pharmacology.
2021 Oct; 14(10):1289-1294. doi:
10.1080/17512433.2021.1964359. [PMID: 34402362] - Takeru Nabeta, Keisuke Kida, Miwa Ishida, Takaaki Shiono, Norio Suzuki, Shunichi Doi, Maya Tsukahara, Yuki Ohta, Tetsuya Kimura, Keita Yamaguchi, Atsushi Takita, Naoki Matsumoto, Yoshihiro J Akashi, Junya Ako, Takayuki Inomata. Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
Clinical pharmacokinetics.
2021 08; 60(8):1061-1071. doi:
10.1007/s40262-021-00999-y. [PMID: 33782831] - Matthieu Bourdin, Delphine Perrotin, Olivier Mathieu, Tristan Herve, François Depasse, Genmin Lu, Pamela B Conley, Geneviève Contant. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
International journal of laboratory hematology.
2021 Aug; 43(4):795-801. doi:
10.1111/ijlh.13591. [PMID: 34092030] - Luigi Cappannoli, Mattia Galli, Raimondo De Cristofaro, Filippo Crea, Domenico D'Amario. Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?.
Journal of the American College of Cardiology.
2021 06; 77(25):3231-3232. doi:
10.1016/j.jacc.2021.03.340. [PMID: 34167650] - Jan Steffel, Christian T Ruff, Elliott M Antman, Eugene Braunwald, Robert P Giugliano. Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?.
Journal of the American College of Cardiology.
2021 06; 77(25):3232-3233. doi:
10.1016/j.jacc.2021.04.066. [PMID: 34167651] - Akira Sezai, Makoto Taoka, Shunji Osaka, Yoshiki Kitazumi, Keito Suzuki, Keita Kamata, Masashi Tanaka. A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2021 Jun; 27(3):191-199. doi:
10.5761/atcs.oa.20-00213. [PMID: 33208579] - Martina Havrdová, Teijo I Saari, Jouko Jalonen, Marko Peltoniemi, Mika Kurkela, Tero Vahlberg, Anri Tienhaara, Janne T Backman, Klaus T Olkkola, Alexey Schramko. Relationship of Edoxaban Plasma Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis.
Journal of clinical pharmacology.
2021 04; 61(4):522-530. doi:
10.1002/jcph.1758. [PMID: 33027547] - Yoshiyuki Morishima, Chikako Kamisato, Yuko Honda. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
2021 Apr; 32(3):209-215. doi:
10.1097/mbc.0000000000001020. [PMID: 33560005] - Takafumi Kato, Tsuyoshi Mikkaichi, Yasushi Yoshigae, Noriko Okudaira, Takako Shimizu, Takashi Izumi, Shuichi Ando, Yoshiaki Matsumoto. Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model.
International journal of pharmaceutics.
2021 Mar; 597(?):120349. doi:
10.1016/j.ijpharm.2021.120349. [PMID: 33545293] - Rachna Patel, Julia Czuprynska, Lara N Roberts, Bipin Vadher, Catherine Rea, Raj Patel, Emma Gee, Gabrielle Saul, Evelyn Coles, Alison Brown, Rosalind Byrne, Vicky Speed, Jignesh P Patel, Roopen Arya. Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.
Thrombosis research.
2021 01; 197(?):192-194. doi:
10.1016/j.thromres.2020.11.004. [PMID: 33227656] - Akira Tamura, Ena Yamamoto, Yoshiyuki Kawano. Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
The American journal of cardiology.
2020 12; 136(?):71-75. doi:
10.1016/j.amjcard.2020.08.047. [PMID: 32946856] - Sameh E Younis, Sara A El-Nahass, Mohammed A W Elkhatib, Sobhi A Soliman, Rasha M Youssef. Gradient HPLC-DAD method for quantification of novel oral anticoagulant 'Edoxaban' in plasma: Its selective determination in presence of sixteen co-administered drugs.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Dec; 1160(?):122386. doi:
10.1016/j.jchromb.2020.122386. [PMID: 32947189] - Noel Chan, Magdalena Sobieraj-Teague, John W Eikelboom. Direct oral anticoagulants: evidence and unresolved issues.
Lancet (London, England).
2020 11; 396(10264):1767-1776. doi:
10.1016/s0140-6736(20)32439-9. [PMID: 33248499] - Elvira Grandone, Filippo Aucella, Doris Barcellona, Giuliano Brunori, Giacomo Forneris, Paolo Gresele, Marco Marietta, Daniela Poli, Sophie Testa, Armando Tripodi, Simonetta C Genovesi. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Blood transfusion = Trasfusione del sangue.
2020 11; 18(6):478-485. doi:
10.2450/2020.0156-20. [PMID: 33000751] - Siri Overstad, Eirik Tjonnfjord, Lamya Garabet, Synne Fronas, Jonas Bergan, Saad Aballi, Waleed Ghanima. Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases.
Thrombosis research.
2020 10; 194(?):116-118. doi:
10.1016/j.thromres.2020.06.032. [PMID: 32788102] - Alexandra A Angheloiu, Yanglan Tan, Cristian Ruse, Scott A Shaffer, George O Angheloiu. In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution.
Drugs in R&D.
2020 Sep; 20(3):217-223. doi:
10.1007/s40268-020-00308-1. [PMID: 32415538] - Yohsuke Sugiyama, Takaaki Tsuchiya, Ryota Tanaka, Aiko Ouchi, Arata Motoyama, Takeshi Takamoto, Natsumi Hara, Yoshitaka Yanagawa. Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2020 Sep; 79(?):30-32. doi:
10.1016/j.jocn.2020.07.038. [PMID: 33070913] - Shun Uemura, Hironori Kobayashi, Yoshinobu Seki, Yuki Okoshi, Hirohito Sone, Nobuhiko Nomoto. Successful Treatment with Edoxaban for Disseminated Intravascular Coagulation in a Case of Aortic Dissection Complicated with Immune Thrombocytopenic Purpura.
Internal medicine (Tokyo, Japan).
2020 Aug; 59(16):2035-2039. doi:
10.2169/internalmedicine.4255-19. [PMID: 32389942] - Basile Chrétien, Marion Sassier, Joachim Alexandre, Véronique Lelong-Boulouard, Charles Dolladille, Sophie Fedrizzi. Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
European journal of clinical pharmacology.
2020 Aug; 76(8):1197-1198. doi:
10.1007/s00228-020-02891-3. [PMID: 32435997] - Saki Ariizumi, Takafumi Naito, Kohei Hoshikawa, Shunta Akutsu, Masao Saotome, Yuichiro Maekawa, Junichi Kawakami. Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Jun; 1146(?):122121. doi:
10.1016/j.jchromb.2020.122121. [PMID: 32361632] - Sophie Testa, Paolo Prandoni, Oriana Paoletti, Rossella Morandini, Maurizio Tala, Claudia Dellanoce, Matteo Giorgi-Pierfranceschi, Monia Betti, Gian Battista Danzi, Angelo Pan, Gualtiero Palareti. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Journal of thrombosis and haemostasis : JTH.
2020 06; 18(6):1320-1323. doi:
10.1111/jth.14871. [PMID: 32329231] - Yating Zhao, Lewis Couchman, Karin Kipper, Roopen Arya, Jignesh P Patel. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 May; 1144(?):122095. doi:
10.1016/j.jchromb.2020.122095. [PMID: 32251991] - Naoki Kiyosawa, Kenji Watanabe, Yoshiyuki Morishima, Takeshi Yamashita, Naoharu Yagi, Takuto Arita, Takayuki Otsuka, Shinya Suzuki. Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation.
International journal of molecular sciences.
2020 Apr; 21(7):. doi:
10.3390/ijms21072444. [PMID: 32244749] - Romain Siriez, Lütfiye Alpan, Kossay Elasaad, Philippe Devel, Julie Laloy, Jean-Michel Dogné, Jonathan Douxfils. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Journal of thrombosis and thrombolysis.
2020 Apr; 49(3):395-403. doi:
10.1007/s11239-019-02030-5. [PMID: 31925664] - Samuel S Shin, Elisabeth B Marsh, Hasan Ali, Paul A Nyquist, Daniel F Hanley, Wendy C Ziai. Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Neurocritical care.
2020 04; 32(2):407-418. doi:
10.1007/s12028-019-00898-y. [PMID: 32034657] - Filipa Gouveia, Joana Bicker, Joana Santos, Marília Rocha, Gilberto Alves, Amílcar Falcão, Ana Fortuna. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Journal of pharmaceutical and biomedical analysis.
2020 Mar; 181(?):113109. doi:
10.1016/j.jpba.2020.113109. [PMID: 31981828] - Vincenzo Russo, Anna Rago, Nunzia Laezza, Pierpaolo Di Micco, Laura Giannetti, Luigi Atripaldi, Antonio D'Onofrio, Paolo Golino, Gerardo Nigro. Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
2020 Mar; 90(1):. doi:
10.4081/monaldi.2020.1224. [PMID: 32204583] - Shinya Suzuki, Yoshiyuki Morishima, Atsushi Takita, Takayuki Otsuka, Naoharu Yagi, Takuto Arita, Takeshi Yamashita. Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).
Heart and vessels.
2020 Mar; 35(3):409-416. doi:
10.1007/s00380-019-01501-2. [PMID: 31522245] - Ling He, Roohi Gajee, Raj Mangaraj, Michael P Waldron, Karen S Brown. Validation and clinical application of dried blood spot assay for quantitative assessment of edoxaban in healthy adults.
Bioanalysis.
2020 Mar; 12(6):393-407. doi:
10.4155/bio-2019-0180. [PMID: 32329378] - Eri Goto, Shigeo Horinaka, Toshihiko Ishimitsu, Toru Kato. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Drug metabolism and pharmacokinetics.
2020 Feb; 35(1):151-159. doi:
10.1016/j.dmpk.2019.10.005. [PMID: 32007354] - Anetta Undas, Leszek Drabik, Tatjana Potpara. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Polish archives of internal medicine.
2020 01; 130(1):47-58. doi:
10.20452/pamw.15136. [PMID: 31933483] - Yoshiyuki Morishima, Chikako Kamisato, Yuko Honda. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
Journal of thrombosis and thrombolysis.
2020 Jan; 49(1):94-99. doi:
10.1007/s11239-019-01929-3. [PMID: 31396790] - Francesco Franchi, Fabiana Rollini, Emilio Garcia, Jose Rivas Rios, Andrea Rivas, Malhar Agarwal, Megha Kureti, Deepa Nagaraju, Mustafa Wali, Maryuri Briceno, Jae Youn Moon, Victor Kairouz, Dmitry Yaranov, Latonya Been, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Theodore A Bass, Dominick J Angiolillo. Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.
2020 Jan; 120(1):83-93. doi:
10.1055/s-0039-1695772. [PMID: 31470444] - Serena Petricciuolo, Alberto Aimo, Raffaele De Caterina. [Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Giornale italiano di cardiologia (2006).
2020 Jan; 21(1):6-15. doi:
10.1714/3285.32585. [PMID: 31960830] - Juraj Sokol, Frantisek Nehaj, Jela Ivankova, Michal Mokan, Lenka Lisa, Jana Zolkova, Lubica Vadelova, Marian Mokan, Jan Stasko. Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2020 Jan; 26(?):1076029620948585. doi:
10.1177/1076029620948585. [PMID: 33054412] - Job Harenberg, Jan Beyer-Westendorf, Mark Crowther, Jonathan Douxfils, Ismail Elalamy, Peter Verhamme, Rupert Bauersachs, Svetlana Hetjens, Christel Weiss. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
Thrombosis and haemostasis.
2020 Jan; 120(1):132-140. doi:
10.1055/s-0039-1700545. [PMID: 31705521] - Shinya Suzuki, Yoshiyuki Morishima, Atsushi Takita, Naoharu Yagi, Takayuki Otsuka, Takuto Arita, Takeshi Yamashita. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Heart and vessels.
2019 Dec; 34(12):2011-2020. doi:
10.1007/s00380-019-01438-6. [PMID: 31123819] - Giuseppe Boriani, Carina Blomström-Lundqvist, Stefan H Hohnloser, Lennart Bergfeldt, Giovanni L Botto, Alessandro Capucci, Ignacio Fernández Lozano, Andreas Goette, Carsten W Israel, José L Merino, A John Camm. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
2019 12; 21(12):1764-1775. doi:
10.1093/europace/euz193. [PMID: 31324921] - Leonardo Di Gennaro, Stefano Lancellotti, Raimondo De Cristofaro, Erica De Candia. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy.
Journal of thrombosis and thrombolysis.
2019 Oct; 48(3):528-531. doi:
10.1007/s11239-019-01866-1. [PMID: 31041653] - Naohiko Takahashi, Yasushi Mukai, Tetsuya Kimura, Keita Yamaguchi, Takuyuki Matsumoto, Hideki Origasa, Ken Okumura. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Circulation journal : official journal of the Japanese Circulation Society.
2019 09; 83(10):2017-2024. doi:
10.1253/circj.cj-19-0535. [PMID: 31511436] - Miho Yamazaki-Nishioka, Minoru Kogiku, Masayuki Noda, Sumio Endo, Mitsuru Takekawa, Hirohisa Kishi, Miki Ota, Yuki Notsu, Makiko Shimizu, Hiroshi Yamazaki. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Xenobiotica; the fate of foreign compounds in biological systems.
2019 Sep; 49(9):1001-1006. doi:
10.1080/00498254.2018.1524188. [PMID: 30216091] - Gerd Mikus, Kathrin I Foerster, Marlene Schaumaeker, Marie-Louise Lehmann, Jürgen Burhenne, Walter E Haefeli. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Clinical pharmacokinetics.
2019 09; 58(9):1155-1163. doi:
10.1007/s40262-019-00749-1. [PMID: 30828771] - Yi-Hsin Chan, Hsin-Fu Lee, Lai-Chu See, Hui-Tzu Tu, Tze-Fan Chao, Yung-Hsin Yeh, Lung-Sheng Wu, Chi-Tai Kuo, Shang-Hung Chang, Gregory Y H Lip. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chest.
2019 09; 156(3):529-543. doi:
10.1016/j.chest.2019.04.108. [PMID: 31103697] - Enrique Chueca Fernández, Amador López Granados, María Del Pilar Zuazola Martínez, Roberto Del Castillo-Medina. Consensus in cardiology on non-vitamin-K oral anticoagulants for patients with atrial fibrillation.
Current medical research and opinion.
2019 09; 35(9):1571-1582. doi:
10.1080/03007995.2019.1605049. [PMID: 30957564] - Yuki Narita, Kana Hamamura, Mami Kashiyama, Sara Utsumi, Yutaka Kakizoe, Yuki Kondo, Yoichi Ishitsuka, Hirofumi Jono, Tetsumi Irie, Masashi Mukoyama, Hideyuki Saito, Daisuke Kadowaki, Sumio Hirata, Kenichiro Kitamura. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
International journal of molecular sciences.
2019 Aug; 20(17):. doi:
10.3390/ijms20174140. [PMID: 31450643] - Mattia Galli, Domenico D'Amario, Felicita Andreotti, Italo Porto, Rocco Vergallo, Mario Sabatelli, Stefano Lancellotti, Emiliana Meleo, Raimondo De Cristofaro, Filippo Crea. Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.
ESC heart failure.
2019 08; 6(4):884-888. doi:
10.1002/ehf2.12434. [PMID: 31184800] - Yoshiyuki Morishima, Yuko Honda. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Journal of thrombosis and thrombolysis.
2019 Jul; 48(1):103-110. doi:
10.1007/s11239-019-01851-8. [PMID: 30972711] - Thomas Sinegre, Mélissa Zlobecki, Eric Doré, Bruno Pereira, Victoria Grèze, Aurélien Lebreton. In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
Thrombosis research.
2019 Jun; 178(?):112-118. doi:
10.1016/j.thromres.2019.04.014. [PMID: 31005667] - Anne-Céline Martin, Eloi Marijon, Kumar Narayanan. Letter by Martin et al Regarding Article, 'Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial'.
Circulation.
2019 04; 139(14):1756-1757. doi:
10.1161/circulationaha.118.037019. [PMID: 30933611] - Sophie Testa, Claudia Dellanoce, Oriana Paoletti, E Cancellieri, Rossella Morandini, Maurizio Tala, Silvia Zambelli, Cristina Legnani. Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function.
Thrombosis research.
2019 Mar; 175(?):61-67. doi:
10.1016/j.thromres.2019.01.008. [PMID: 30721819] - Nishank Jain, Robert F Reilly. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Clinical journal of the American Society of Nephrology : CJASN.
2019 02; 14(2):278-287. doi:
10.2215/cjn.02170218. [PMID: 29802125] - Jordanne Feldberg, Param Patel, Ashley Farrell, Sylvia Sivarajahkumar, Karen Cameron, Jennifer Ma, Marisa Battistella. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2019 02; 34(2):265-277. doi:
10.1093/ndt/gfy031. [PMID: 29509922] - Fakiha Siddiqui, Debra Hoppensteadt, Walter Jeske, Omer Iqbal, Alfonso Tafur, Jawed Fareed. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2019 Jan; 25(?):1076029619847524. doi:
10.1177/1076029619847524. [PMID: 31088146] - Fakiha Siddiqui, Alfonso Tafur, Lorenzo Storino Ramacciotti, Walter Jeske, Debra Hoppensteadt, Eduardo Ramacciotti, Omer Iqbal, Jawed Fareed. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2019 Jan; 25(?):1076029619863493. doi:
10.1177/1076029619863493. [PMID: 31298056] - Andreas Hillarp, Karin Strandberg, Fariba Baghaei, Inger Fagerberg Blixter, Kerstin M Gustafsson, Tomas L Lindahl. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Scandinavian journal of clinical and laboratory investigation.
2018 Nov; 78(7-8):575-583. doi:
10.1080/00365513.2018.1522664. [PMID: 30278787] - Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Andreas Hammerschmidt, Doris Hendig, Isabel Faust, Cornelius Knabbe, Ingvild Birschmann. Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Clinica chimica acta; international journal of clinical chemistry.
2018 Nov; 486(?):347-356. doi:
10.1016/j.cca.2018.08.017. [PMID: 30114406] - Austin Hu, Jingbo Niu, Wolfgang C Winkelmayer. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Seminars in nephrology.
2018 11; 38(6):618-628. doi:
10.1016/j.semnephrol.2018.08.006. [PMID: 30413255] - Giovanni Fazio, Ilaria Dentamaro, Rosanna Gambacurta, Pasquale Alcamo, Paolo Colonna. Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment.
Clinical drug investigation.
2018 Nov; 38(11):1023-1030. doi:
10.1007/s40261-018-0693-6. [PMID: 30191509] - Ophelia Q P Yin, Elliott M Antman, Eugene Braunwald, Michele F Mercuri, Raymond Miller, David Morrow, Christian T Ruff, Kenneth Truitt, Jeffrey I Weitz, Robert P Giugliano. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Circulation.
2018 10; 138(18):1963-1973. doi:
10.1161/circulationaha.118.033933. [PMID: 29967197] - Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami, Kenshi Takechi, Licht Miyamoto, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya, Toshiaki Tamaki. Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Scientific reports.
2018 Jul; 8(1):10858. doi:
10.1038/s41598-018-29008-2. [PMID: 30022146] - Kazuhiko Hanada, Shin-Ichi Matsumoto, Soichi Shibata, Hajime Matsubara, Yasunori Tsukimura, Harumi Takahashi. A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty.
Biomedical chromatography : BMC.
2018 Jun; 32(6):e4213. doi:
10.1002/bmc.4213. [PMID: 29451685] - Sofia Lindahl, Roar Dyrkorn, Olav Spigset, Solfrid Hegstad. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Therapeutic drug monitoring.
2018 06; 40(3):369-376. doi:
10.1097/ftd.0000000000000509. [PMID: 29578938] - Nilufar Mohebbi. [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Praxis.
2018 Jun; 107(13):683-687. doi:
10.1024/1661-8157/a003005. [PMID: 29921184] - Adna Ašić, Damir Marjanović, Jure Mirat, Dragan Primorac. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Personalized medicine.
2018 05; 15(3):209-221. doi:
10.2217/pme-2017-0092. [PMID: 29767545] - Kenneth Duchin, Anil Duggal, George J Atiee, Motonori Kidokoro, Tadanobu Takatani, Nicole Lazarus Shipitofsky, Ling He, George Zhang, Tarundeep Kakkar. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Clinical pharmacokinetics.
2018 02; 57(2):221-228. doi:
10.1007/s40262-017-0554-0. [PMID: 28512699] - A G Vandell, J Lee, M Shi, I Rubets, K S Brown, J R Walker. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
The pharmacogenomics journal.
2018 01; 18(1):153-159. doi:
10.1038/tpj.2016.82. [PMID: 27897269] - Yuko Honda, Taketoshi Furugohri, Yoshiyuki Morishima. Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.
Pharmacology.
2018; 101(1-2):92-95. doi:
10.1159/000484172. [PMID: 29131074] - Genmin Lu, Polly Pine, Janet M Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, John Malinowski, Stanley J Hollenbach, John T Curnutte, Pamela B Conley. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
PloS one.
2018; 13(3):e0195122. doi:
10.1371/journal.pone.0195122. [PMID: 29590221] - Hideaki Oka, Taro Kamimura, Yuki Hiramatsu, Kento Fukumitsu, Rei Iwata, Mika Kondo, Yutaro Hirashima, Seishi Aihara, Atsumi Harada, Kazuhiko Tsuruya. Cholesterol Crystal Embolism Induced by Direct Factor Xa Inhibitor: A First Case Report.
Internal medicine (Tokyo, Japan).
2018 Jan; 57(1):71-74. doi:
10.2169/internalmedicine.8660-16. [PMID: 28943551] - Vinod K Bansal, Charles A Herzog, Mark J Sarnak, Michael J Choi, Ravindra Mehta, Bernard G Jaar, Michael V Rocco, Holly Kramer. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 Dec; 70(6):859-868. doi:
10.1053/j.ajkd.2017.08.003. [PMID: 28941763] - Miho Kimachi, Toshi A Furukawa, Kimihiko Kimachi, Yoshihito Goto, Shingo Fukuma, Shunichi Fukuhara. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
The Cochrane database of systematic reviews.
2017 Nov; 11(?):CD011373. doi:
10.1002/14651858.cd011373.pub2. [PMID: 29105079] - Wei Song, Hongbo Ci, Guanglei Tian, Yanjun Zhang, Xiaohu Ge. Edoxaban improves venous thrombosis via increasing hydrogen sulfide and homocysteine in rat model.
Molecular medicine reports.
2017 Nov; 16(5):7706-7714. doi:
10.3892/mmr.2017.7574. [PMID: 28944880] - Gregory Y H Lip, Naab Al-Saady, Michael D Ezekowitz, Maciej Banach, Andreas Goette. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
American heart journal.
2017 Nov; 193(?):16-22. doi:
10.1016/j.ahj.2017.07.010. [PMID: 29129251] - Kunihiko Nagakari, Mari Emmi, Toshiaki Iba. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2017 Sep; 23(6):677-684. doi:
10.1177/1076029616638506. [PMID: 26984934] - John Fanikos, Allison E Burnett, Charles E Mahan, Paul P Dobesh. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
The American journal of medicine.
2017 09; 130(9):1015-1023. doi:
10.1016/j.amjmed.2017.04.015. [PMID: 28502818] - Martin H J Wiesen, Cornelia Blaich, Thomas Streichert, Guido Michels, Carsten Müller. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Clinical chemistry and laboratory medicine.
2017 Aug; 55(9):1349-1359. doi:
10.1515/cclm-2016-0888. [PMID: 28328524] - Ling He, Jarema Kochan, Min Lin, Alexander Vandell, Karen Brown, Francois Depasse. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
Thrombosis research.
2017 Jul; 155(?):121-127. doi:
10.1016/j.thromres.2017.05.005. [PMID: 28535438] - Xia Chen, Dongyang Liu, Yiwen Wu, Hanlin Song, Yang Liu, Ji Jiang, Pei Hu. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Jul; 47(7):592-599. doi:
10.1080/00498254.2016.1207825. [PMID: 27560456] - L Di Lullo, C Ronco, M Cozzolino, D Russo, L Russo, B Di Iorio, A De Pascalis, V Barbera, M Galliani, E Vitaliano, C Campana, F Santoboni, A Bellasi. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Thrombosis research.
2017 Jul; 155(?):38-47. doi:
10.1016/j.thromres.2017.04.027. [PMID: 28482261] - John W Eikelboom, Daniel J Quinlan, Jack Hirsh, Stuart J Connolly, Jeffrey I Weitz. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
JAMA cardiology.
2017 05; 2(5):566-574. doi:
10.1001/jamacardio.2017.0364. [PMID: 28355459] - Xia Chen, Dongyang Liu, Yiwen Wu, Yang Liu, Hanlin Song, Ji Jiang, Pei Hu. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
International journal of clinical pharmacology and therapeutics.
2017 Mar; 55(3):256-263. doi:
10.5414/cp202737. [PMID: 28025966] - Inmaculada Hernandez, Kenneth J Smith, Yuting Zhang. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Thrombosis research.
2017 Feb; 150(?):123-130. doi:
10.1016/j.thromres.2016.10.006. [PMID: 27771008] - Tanya R Riley, Mary L Gauthier-Lewis, Chelsea K Sanchez, Janine S Douglas. Role of agents for reversing the effects of target-specific oral anticoagulants.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2017 Jan; 74(2):54-61. doi:
10.2146/ajhp150810. [PMID: 27895055] - Rahul Trikha, Peter R Kowey. Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants.
Cardiology.
2017 ; 136(2):115-124. doi:
10.1159/000447530. [PMID: 27595409] - Jürgen Koscielny, Christoph Rosenthal, Christian von Heymann. Update on Direct Oral AntiCoagulants (DOACs).
Hamostaseologie.
2017; 37(4):267-275. doi:
10.5482/hamo-16-10-0041. [PMID: 29582929] - Dolly A Parasrampuria, Jeanne Mendell, Minggao Shi, Nobuko Matsushima, Hamim Zahir, Kenneth Truitt. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
British journal of clinical pharmacology.
2016 12; 82(6):1591-1600. doi:
10.1111/bcp.13092. [PMID: 27530188] - Sean D Pokorney, Peter Shrader, Laine Thomas, Gregg C Fonarow, Peter R Kowey, Daniel E Singer, Jack Ansell, Bernard J Gersh, Kenneth W Mahaffey, Elaine M Hylek, Alan S Go, Jonathan P Piccini, Eric D Peterson. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.
Circulation.
2016 10; 134(15):1122-1124. doi:
10.1161/circulationaha.116.024333. [PMID: 27753615]